

Resource Summary Report

Generated by [kravitz2](#) on Aug 13, 2026

TotalSeq(TM)-C0063 anti-human CD45RA

RRID:AB_2800764

Type: Antibody

Proper Citation

BioLegend Cat# 304163, RRID:AB_2800764

Antibody Information

URL: http://antibodyregistry.org/AB_2800764

Proper Citation: BioLegend Cat# 304163, RRID:AB_2800764

Target Antigen: CD45RA

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: PG

Antibody Name: TotalSeq(TM)-C0063 anti-human CD45RA

Description: This monoclonal targets CD45RA

Target Organism: human

Clone ID: Clone HI100

Antibody ID: AB_2800764

Vendor: BioLegend

Catalog Number: 304163

Record Creation Time: 20250819T231615+0000

Record Last Update: 20250820T044903+0000

Ratings and Alerts

No rating or validation information has been found for TotalSeq(TM)-C0063 anti-human CD45RA.

No alerts have been found for TotalSeq(TM)-C0063 anti-human CD45RA.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Kocher K, et al. (2026) Integrating complementary approaches reveals antigen-reactive CD4+ T cell states after SARS-CoV-2 vaccination. iScience, 29(6), 116175.

La C, et al. (2026) In vivo modeling of human ?? T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 V?2 T cell development. Cell reports, 45(2), 116977.

Spangler A, et al. (2025) Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later. Immunity, 58(3), 728.

Perez CR, et al. (2025) Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence. Cell systems, 16(5), 101260.

Buus TB, et al. (2025) Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer. Cancer discovery, 15(10), 2036.

Sureshchandra S, et al. (2025) Deep profiling of human T cells defines compartmentalized clones and phenotypic trajectories across blood and tonsils. Immunity, 58(12), 3130.

Lee H, et al. (2025) TCR signaling via NFATc1 constrains IL-15-induced bystander activation of human memory CD8+ T cells. Immunity, 58(12), 2957.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell reports. Medicine, 5(7), 101628.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. Cell reports. Medicine, 5(7), 101620.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. Cell reports methods, 3(1), 100388.

Povoleri GAM, et al. (2023) Psoriatic and rheumatoid arthritis joints differ in the composition of CD8+ tissue-resident memory T cell subsets. *Cell reports*, 42(5), 112514.

Ivanova EN, et al. (2023) mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. *iScience*, 26(12), 108572.

Terekhova M, et al. (2023) Single-cell atlas of healthy human blood unveils age-related loss of NKG2C+GZMB-CD8+ memory T cells and accumulation of type 2 memory T cells. *Immunity*, 56(12), 2836.

Mayer-Blackwell K, et al. (2023) mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RA^{int} TEMRA-like CD8+ T cells in COVID-19 recovered individuals. *Cell reports. Medicine*, 4(8), 101149.

Sureshchandra S, et al. (2023) Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity. *Cell reports*, 42(7), 112769.

Zwijnenburg AJ, et al. (2023) Graded expression of the chemokine receptor CX3CR1 marks differentiation states of human and murine T cells and enables cross-species interpretation. *Immunity*, 56(8), 1955.

Gao Y, et al. (2022) Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. *Immunity*, 55(9), 1732.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Yu B, et al. (2022) Engineered cell entry links receptor biology with single-cell genomics. *Cell*, 185(26), 4904.